JP2010516626A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010516626A5 JP2010516626A5 JP2009545734A JP2009545734A JP2010516626A5 JP 2010516626 A5 JP2010516626 A5 JP 2010516626A5 JP 2009545734 A JP2009545734 A JP 2009545734A JP 2009545734 A JP2009545734 A JP 2009545734A JP 2010516626 A5 JP2010516626 A5 JP 2010516626A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cyclodextrin
- pharmaceutical composition
- composition according
- iodo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 33
- 229920000858 Cyclodextrin Polymers 0.000 claims 24
- 206010028980 Neoplasm Diseases 0.000 claims 19
- 201000011510 cancer Diseases 0.000 claims 18
- 239000001116 FEMA 4028 Substances 0.000 claims 17
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 17
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 17
- 229960004853 betadex Drugs 0.000 claims 17
- 125000001424 substituent group Chemical group 0.000 claims 15
- 239000008363 phosphate buffer Substances 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 10
- MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 claims 9
- 206010006187 Breast cancer Diseases 0.000 claims 7
- 208000026310 Breast neoplasm Diseases 0.000 claims 7
- 206010033128 Ovarian cancer Diseases 0.000 claims 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- -1 hydroxy, amino, nitro, iodo Chemical group 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000001246 bromo group Chemical group Br* 0.000 claims 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000002346 iodo group Chemical group I* 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 206010039491 Sarcoma Diseases 0.000 claims 4
- 208000032383 Soft tissue cancer Diseases 0.000 claims 4
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 claims 3
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims 2
- MSRRMIHJGQJADR-UHFFFAOYSA-N 4-iodo-2-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C=C1[N+]([O-])=O MSRRMIHJGQJADR-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000000728 Thymus Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 210000002556 adrenal cortex cell Anatomy 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000002797 childhood leukemia Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000003884 gestational trophoblastic disease Diseases 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 201000006866 hypopharynx cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000026807 lung carcinoid tumor Diseases 0.000 claims 1
- 201000003175 male breast cancer Diseases 0.000 claims 1
- 208000010907 male breast carcinoma Diseases 0.000 claims 1
- 208000006178 malignant mesothelioma Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 210000003928 nasal cavity Anatomy 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 201000006958 oropharynx cancer Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 201000002511 pituitary cancer Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 208000037968 sinus cancer Diseases 0.000 claims 1
- 201000008261 skin carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 208000037965 uterine sarcoma Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 0 *c1c(*)c(*)c(C(N)=O)c(*)c1* Chemical compound *c1c(*)c(*)c(C(N)=O)c(*)c1* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88075507P | 2007-01-16 | 2007-01-16 | |
| PCT/US2008/051214 WO2008089272A1 (en) | 2007-01-16 | 2008-01-16 | Formulations for cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010516626A JP2010516626A (ja) | 2010-05-20 |
| JP2010516626A5 true JP2010516626A5 (OSRAM) | 2011-03-03 |
Family
ID=39350967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009545734A Withdrawn JP2010516626A (ja) | 2007-01-16 | 2008-01-16 | ガン治療剤 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20080176946A1 (OSRAM) |
| EP (2) | EP2121139B1 (OSRAM) |
| JP (1) | JP2010516626A (OSRAM) |
| KR (1) | KR20090113852A (OSRAM) |
| CN (1) | CN101668561A (OSRAM) |
| AU (1) | AU2008206294A1 (OSRAM) |
| BR (1) | BRPI0806590A2 (OSRAM) |
| CA (1) | CA2674600A1 (OSRAM) |
| CO (1) | CO6220840A2 (OSRAM) |
| CR (1) | CR10975A (OSRAM) |
| CY (1) | CY1113819T1 (OSRAM) |
| DK (1) | DK2121139T3 (OSRAM) |
| DO (1) | DOP2009000178A (OSRAM) |
| EC (1) | ECSP099577A (OSRAM) |
| ES (1) | ES2395690T3 (OSRAM) |
| GB (1) | GB2447796C (OSRAM) |
| GT (1) | GT200900201A (OSRAM) |
| HR (1) | HRP20120960T1 (OSRAM) |
| IL (1) | IL199682A0 (OSRAM) |
| MA (1) | MA34559B1 (OSRAM) |
| MX (1) | MX2009007596A (OSRAM) |
| NZ (1) | NZ579098A (OSRAM) |
| PL (1) | PL2121139T3 (OSRAM) |
| PT (1) | PT2121139E (OSRAM) |
| RS (1) | RS52633B (OSRAM) |
| RU (2) | RU2481830C2 (OSRAM) |
| SG (1) | SG178714A1 (OSRAM) |
| SI (1) | SI2121139T1 (OSRAM) |
| SV (1) | SV2009003335A (OSRAM) |
| TN (1) | TN2009000292A1 (OSRAM) |
| UA (1) | UA100852C2 (OSRAM) |
| WO (1) | WO2008089272A1 (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7961081B2 (en) * | 2003-05-22 | 2011-06-14 | John Tomlienovic | Anti-theft system and method |
| KR20080031266A (ko) * | 2005-06-10 | 2008-04-08 | 바이파 사이언스 인코포레이티드 | Ｐａｒｐ 조절제 및 암의 치료 |
| SG164368A1 (en) | 2005-07-18 | 2010-09-29 | Bipar Sciences Inc | Treatment of cancer |
| US20070292883A1 (en) * | 2006-06-12 | 2007-12-20 | Ossovskaya Valeria S | Method of treating diseases with PARP inhibitors |
| US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| US20100160442A1 (en) * | 2006-07-18 | 2010-06-24 | Ossovskaya Valeria S | Formulations for cancer treatment |
| US7538252B2 (en) * | 2006-09-05 | 2009-05-26 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
| CA2662517A1 (en) | 2006-09-05 | 2008-03-13 | Jerome Moore | Treatment of cancer |
| CA2662337A1 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
| US20090149417A1 (en) * | 2007-10-19 | 2009-06-11 | Valeria Ossovskaya | Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors |
| RU2480211C2 (ru) | 2007-11-12 | 2013-04-27 | Байпар Сайенсиз, Инк. | Лечение рака молочной железы с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами |
| AU2009212401A1 (en) * | 2008-02-04 | 2009-08-13 | Bipar Sciences, Inc. | Methods of diagnosing and treating PARP-mediated diseases |
| US8026271B2 (en) * | 2008-07-11 | 2011-09-27 | National Health Research Institutes | Formulations of indol-3-yl-2-oxoacetamide compounds |
| WO2010036226A1 (en) * | 2008-09-26 | 2010-04-01 | George Nelson | Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis |
| MX2011003277A (es) * | 2008-10-14 | 2012-09-21 | Salubrious Pharmaceuticals LLC | Proceso para el tratamiento de la artritis reumatoide, temblores/enfermedad de parkinson, esclerosis multiple y cancer de tipo no viral. |
| EP2709618A4 (en) * | 2011-05-10 | 2014-11-05 | UNIVERSITé LAVAL | METHOD FOR THE TREATMENT AND DIAGNOSIS OF PULMONARY ARTERIAL HYPERTENSION |
| IN2015DN04094A (OSRAM) * | 2012-11-30 | 2015-10-09 | Glaxosmithkline Llc | |
| WO2017192618A1 (en) * | 2016-05-02 | 2017-11-09 | Symbios Technologies, Inc. | Electrochemical plasma activated aqueous chemotherapeutics |
| EP3655418A4 (en) | 2017-06-22 | 2021-05-19 | Triact Therapeutics, Inc. | GLIOBLASTOMA TREATMENT METHODS |
| KR20250016494A (ko) | 2017-09-26 | 2025-02-03 | 테사로, 인코포레이티드 | 니라파립 제제 |
| US11628144B2 (en) | 2017-09-29 | 2023-04-18 | Triact Therapeutics, Inc. | Iniparib formulations and uses thereof |
| WO2020246737A1 (ko) * | 2019-06-04 | 2020-12-10 | 사회복지법인 삼성생명공익재단 | 콰시노이드를 포함하는 거세 저항성 전립선암 치료용 조성물 |
| CZ309587B6 (cs) * | 2021-01-22 | 2023-05-03 | Oncora S.R.O. | Mikroemulzní prekoncentrát s obsahem kladribinu a způsob jeho přípravy |
| GB2611315B (en) * | 2021-09-29 | 2024-01-03 | Siemens Healthcare Gmbh | Method of operating a magnetic resonance scanner |
| WO2023239919A1 (en) * | 2022-06-10 | 2023-12-14 | Dana-Farber Cancer Institute, Inc. | Allelic imbalance of chromatin accessibility in cancer identifies causal risk variants and their mechanisms |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0348655A (ja) * | 1989-07-14 | 1991-03-01 | Shionogi & Co Ltd | プロスタグランジンｄ↓２類の安定化 |
| US5633282A (en) * | 1990-05-25 | 1997-05-27 | British Technology Group Limited | Inhibition of viral infection |
| US5232735A (en) * | 1990-06-01 | 1993-08-03 | Bioresearch, Inc. | Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers |
| US5637618A (en) * | 1990-06-01 | 1997-06-10 | Bioresearch, Inc. | Specific eatable taste modifiers |
| US5631038A (en) * | 1990-06-01 | 1997-05-20 | Bioresearch, Inc. | Specific eatable taste modifiers |
| US5484951A (en) * | 1990-10-19 | 1996-01-16 | Octamer, Incorporated | 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents |
| US5652260A (en) * | 1991-10-22 | 1997-07-29 | Octamer, Inc. | Adenosine diphosphoribose polymerase binding nitroso aromatic compound useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents |
| US5482975A (en) * | 1991-10-22 | 1996-01-09 | Octamer, Inc. | Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents |
| US5877185A (en) * | 1991-10-22 | 1999-03-02 | Octamer, Inc. | Synergistic compositions useful as anti-tumor agents |
| US5516941A (en) * | 1991-10-22 | 1996-05-14 | Octamer, Inc. | Specific inactivators of "retroviral" (asymmetric) zinc fingers |
| US5464871A (en) * | 1993-05-12 | 1995-11-07 | Octamer, Inc. | Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents |
| GB9200247D0 (en) * | 1992-01-07 | 1992-02-26 | Erba Carlo Spa | Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation |
| US5558855A (en) | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
| US6008250A (en) * | 1993-05-26 | 1999-12-28 | Bioresearch, Inc. | Specific eatable taste modifiers |
| US6015792A (en) * | 1993-05-26 | 2000-01-18 | Bioresearch, Inc. | Specific eatable taste modifiers |
| US5589483A (en) * | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
| AU5780696A (en) * | 1995-06-02 | 1996-12-18 | Takeda Chemical Industries Ltd. | Stabilized composition comprising an antiulcerative benzimid azole |
| US5837729A (en) * | 1996-04-26 | 1998-11-17 | Metatron, Inc. | Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof |
| US6225323B1 (en) * | 1997-04-10 | 2001-05-01 | Joseph Koziak | Activated iododerivatives for the treatment of cancer and AIDS |
| US5908861A (en) * | 1997-05-13 | 1999-06-01 | Octamer, Inc. | Methods for treating inflammation and inflammatory disease using pADPRT inhibitors |
| US6696426B2 (en) * | 2000-08-22 | 2004-02-24 | Pharmacia Corporation | Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems |
| WO2002055076A1 (en) * | 2001-01-04 | 2002-07-18 | Daiichi Pharmaceutical Co., Ltd. | Cyclodextrin-containing pharmaceutical preparation |
| US20050113283A1 (en) * | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| JP2003321364A (ja) * | 2002-05-07 | 2003-11-11 | Eisai Co Ltd | シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物 |
| JP2006516034A (ja) * | 2003-01-14 | 2006-06-15 | テバ ファーマシューティカル インダストリーズ リミティド | 全身性エリテマトーデスを治療するためのペプチドの非経口製剤 |
| WO2005023765A1 (en) * | 2003-09-11 | 2005-03-17 | Pharmacia & Upjohn Company Llc | Method for catalyzing amidation reactions by the presence of co2 |
| KR20080031266A (ko) * | 2005-06-10 | 2008-04-08 | 바이파 사이언스 인코포레이티드 | Ｐａｒｐ 조절제 및 암의 치료 |
| SG164368A1 (en) * | 2005-07-18 | 2010-09-29 | Bipar Sciences Inc | Treatment of cancer |
| US20070292883A1 (en) * | 2006-06-12 | 2007-12-20 | Ossovskaya Valeria S | Method of treating diseases with PARP inhibitors |
| US7538252B2 (en) * | 2006-09-05 | 2009-05-26 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
| CA2662337A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
| CA2662335A1 (en) * | 2006-09-05 | 2008-03-13 | Valeria Ossovskaya | Methods for designing parp inhibitors and uses thereof |
| CA2662517A1 (en) * | 2006-09-05 | 2008-03-13 | Jerome Moore | Treatment of cancer |
-
2008
- 2008-01-16 AU AU2008206294A patent/AU2008206294A1/en not_active Withdrawn
- 2008-01-16 RU RU2009130599/15A patent/RU2481830C2/ru not_active IP Right Cessation
- 2008-01-16 MA MA32171A patent/MA34559B1/fr unknown
- 2008-01-16 CA CA002674600A patent/CA2674600A1/en not_active Withdrawn
- 2008-01-16 PL PL08727771T patent/PL2121139T3/pl unknown
- 2008-01-16 JP JP2009545734A patent/JP2010516626A/ja not_active Withdrawn
- 2008-01-16 KR KR1020097017060A patent/KR20090113852A/ko not_active Withdrawn
- 2008-01-16 BR BRPI0806590-0A patent/BRPI0806590A2/pt not_active Application Discontinuation
- 2008-01-16 HR HRP20120960AT patent/HRP20120960T1/hr unknown
- 2008-01-16 MX MX2009007596A patent/MX2009007596A/es active IP Right Grant
- 2008-01-16 GB GB0807263A patent/GB2447796C/en not_active Withdrawn - After Issue
- 2008-01-16 DK DK08727771.1T patent/DK2121139T3/da active
- 2008-01-16 SG SG2012003109A patent/SG178714A1/en unknown
- 2008-01-16 CN CN200880008617A patent/CN101668561A/zh active Pending
- 2008-01-16 SI SI200830855T patent/SI2121139T1/sl unknown
- 2008-01-16 WO PCT/US2008/051214 patent/WO2008089272A1/en not_active Ceased
- 2008-01-16 PT PT87277711T patent/PT2121139E/pt unknown
- 2008-01-16 NZ NZ579098A patent/NZ579098A/en not_active IP Right Cessation
- 2008-01-16 EP EP08727771A patent/EP2121139B1/en active Active
- 2008-01-16 UA UAA200908564A patent/UA100852C2/ru unknown
- 2008-01-16 ES ES08727771T patent/ES2395690T3/es active Active
- 2008-01-16 US US12/015,403 patent/US20080176946A1/en not_active Abandoned
- 2008-01-16 RS RS20120544A patent/RS52633B/sr unknown
- 2008-01-16 EP EP11192725A patent/EP2476461A3/en not_active Withdrawn
-
2009
- 2009-07-02 IL IL199682A patent/IL199682A0/en unknown
- 2009-07-07 TN TNP2009000292A patent/TN2009000292A1/fr unknown
- 2009-07-14 DO DO2009000178A patent/DOP2009000178A/es unknown
- 2009-07-15 GT GT200900201A patent/GT200900201A/es unknown
- 2009-07-15 SV SV2009003335A patent/SV2009003335A/es unknown
- 2009-08-13 EC EC2009009577A patent/ECSP099577A/es unknown
- 2009-08-14 CR CR10975A patent/CR10975A/es unknown
- 2009-08-14 CO CO09085583A patent/CO6220840A2/es not_active Application Discontinuation
-
2012
- 2012-12-03 RU RU2012151571/15A patent/RU2012151571A/ru unknown
-
2013
- 2013-01-09 CY CY20131100023T patent/CY1113819T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010516626A5 (OSRAM) | ||
| RU2481830C2 (ru) | Лекарственные препараты для лечения рака | |
| JP2017530171A5 (OSRAM) | ||
| JP2014193925A5 (OSRAM) | ||
| JP2013522292A5 (OSRAM) | ||
| JP2016040288A5 (OSRAM) | ||
| JP2018510139A5 (OSRAM) | ||
| JP2018518537A5 (OSRAM) | ||
| JP2013534535A5 (OSRAM) | ||
| JP2014012726A5 (OSRAM) | ||
| JP2017517538A5 (OSRAM) | ||
| CU23967B1 (es) | Derivados de pirazin-2-carboxamida para tratar enfermedades mediadas por el bloqueo del canal de sodio epitelial | |
| JP2010514797A5 (OSRAM) | ||
| JP2008525530A5 (OSRAM) | ||
| RU2015154275A (ru) | Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf | |
| JP2013507415A5 (OSRAM) | ||
| JP2015529235A5 (OSRAM) | ||
| JP2015505296A5 (OSRAM) | ||
| JP2013537203A5 (OSRAM) | ||
| JP2009534457A5 (OSRAM) | ||
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
| JP2016501838A5 (OSRAM) | ||
| JP2014528464A5 (OSRAM) | ||
| JP2010209101A5 (OSRAM) | ||
| JP2013544892A5 (OSRAM) |